R&D News | pharmaphorum

News

EU regulators begin fast review of dexamethasone for COVID-1...

European regulators have begun a speedy review of dexamethasone as a treatment for adults hospitalised with COVID-19, a potentially cheaper option to aid recovery than Gilead’s Veklury.

News

Gilead licenses Jounce immunotherapy for $800m

Gilead has joined forces with biotech Jounce Therapeutics to licence its immunotherapy JTX-1811 in a deal worth more than $800 million.

News

MHRA publishes guidance on medicine regulation after Brexit

The UK’s medicines regulator has published long-awaited guidance on regulation of medicines and medical devices as the UK approaches the end of its Brexit transition period at the end of th

News

GSK and Vir take COVID-19 antibody therapy into clinic

GlaxoSmithKline and US-based Vir Biotechnology are to trial a new therapy for COVID-19 based on an antibody designed to neutralise the SARS-CoV-2 coronavirus.

News

AZ expands phase 3 trials of COVID-19 vaccine frontrunner in...

AstraZeneca has expanded development of COVID-19 vaccine AZD1222 into the US, beginning a phase 3 clinical trial across all adult age groups.

News

Sanofi/Regeneron's Kevzara fails again in serious COVID-19 c...

Sanofi has drawn another blank in its attempt to repurpose its IL-6 drug Kevzara to tackle the extreme immune reaction seen in serious cases of COVID-19.

EU regulators begin fast review of dexamethasone for COVID-1...

Gilead licenses Jounce immunotherapy for $800m

MHRA publishes guidance on medicine regulation after Brexit

GSK and Vir take COVID-19 antibody therapy into clinic

AZ expands phase 3 trials of COVID-19 vaccine frontrunner in...

Sanofi/Regeneron's Kevzara fails again in serious COVID-19 c...

Third Rock in $2bn drug-hunting pact with China's Funnel

Securing your ROI: Turning post-acquisition integration into...

News

Editor's Picks